Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3

Human Molecular Genetics

Volumn 18, Issue 24, 2009, Pages 4843-4852

  Jung, Joonil ^a,c   Xu, Kexiang ^a   Lessing, Derek ^a,b   Bonini, Nancy M ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIN 3; CASPASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DROSOPHILA; GENE MUTATION; GENOMIC FRAGMENT; GENOTYPE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MACHADO JOSEPH DISEASE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; TRANSGENE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CASPASES; CELL LINE; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DROSOPHILA MELANOGASTER; HUMANS; MACHADO-JOSEPH DISEASE; MICE; MUTAGENESIS, SITE-DIRECTED; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; REPRESSOR PROTEINS;

MAMMALIA; MUS MUSCULUS;

EID: 70450191208     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp456     Document Type: Article

References (27)

1. Beher, D. (2008) Gamma-secretase modulation and its promise for Alzheimer's disease: A rationale for drug discovery. Curr. Top. Med. Chem., 8, 34-37.
2. Rohn, T.T. and Head, E. (2009) Caspases as therapeutic targets in Alzheimer's disease: Is it time to 'cut' to the chase? Int. J. Clin. Exp. Pathol., 2, 108-118.
3. Gamblin, T.C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A.L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N. et al. (2003) Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. USA, 100, 10032-10037.
4. Newman, J., Rissman, R.A., Sarsoza, F., Kim, R.C., Dick, M., Bennett, D.A., Cotman, C.W., Rohn, T.T. and Head, E. (2005) Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol., 110, 135-144.
5. Hoffner, G., Island, M.L. and Djian, P. (2005) Purification of neuronal inclusions of patients with Huntington's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J. Neurochem., 95, 125-136.
6. Graham, R.K., Deng, Y., Slow, E.J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., Bertram, L., Murphy, Z. et al. (2006) Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell, 125, 1179-1191.
7. Goti, D., Katzen, S.M., Mez, J., Kurtis, N., Kiluk, J., Ben-Haiem, L., Jenkins, N.A., Copeland, N.G., Kakizuka, A., Sharp, A.H. et al. (2004) A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J. Neurosci., 24, 10266-10279.
8. Colomer Gould, V.F., Goti, D., Pearce, D., Gonzalez, G.A., Gao, H., Bermudez de Leon, M., Jenkins, N.A., Copeland, N.G., Ross, C.A. and Brown, D.R. (2007) A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol. Dis., 27, 362-369.
9. Berke, S.J., Schmied, F.A., Brunt, E.R., Ellerby, L.M. and Paulson, H.L. (2004) Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J. Neurochem., 89, 908-918.
10. Jung, J. and Bonini, N. (2007) CREB-binding protein modulates repeat instability in a Drosophila model for polyQ disease. Science 315, 1857-1859.
11. Lessing, D. and Bonini, N.M. (2008) Polyglutamine genes interact to modulate the severity and progression of neurodegeneration in Drosophila. PLoS Biol., 6, 266-274.
12. Li, L.B., Yu, Z., Teng, X. and Bonini, N.M. (2008) RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature, 453 1107-1011.
13. Warrick, J.M., Morabito, L.M., Bilen, J., Gordesky-Gold, B., Faust, L.Z., Paulson, H.L. and Bonini, N.M. (2005) Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell, 18, 37-48.
14. Burnett, B., Li, F. and Pittman, R.N. (2003) The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet., 12, 3195-3205.
15. Burnett, B.G. and Pittman, R.N. (2005) The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc. Natl Acad. Sci. USA, 102, 4330-4335.
16. Winborn, B.J., Travis, S.M., Todi, S.V., Scaglione, K.M., Xu, P., Williams, A.J., Cohen, R.E., Peng, J. and Paulson, H.L. (2008) The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J. Biol. Chem., 283, 26436-26443.
17. Boeddrich, A., Gaumer, S., Haacke, A., Tzvetkov, N., Albrecht, M., Evert, B.O., Muller, E.C., Lurz, R., Breuer, P., Schugardt, N. et al. (2006) An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J., 25, 1547-1558.
18. Haacke, A., Hartl, F.U. and Breuer, P. (2007) Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J. Biol. Chem., 282, 18851-18856.
19. Pozzi, C., Valtorta, M., Tedeschi, G., Galbusera, E., Pastori, V., Bigi, A., Nonnis, S., Grassi, E. and Fusi, P. (2008) Study of subcellular localization and proteolysis of ataxin-3. Neurobiol. Dis., 30 190-200.
20. Stenoien, D.L., Mielke, M. and Mancini, M.A. (2002) Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components. Nat. Cell Biol., 4, 806-810.
21. Steffan, J.S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.Z., Gohler, H., Wanker, E.E., Bates, G.P., Housman, D.E. and Thompson, L.M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA, 97, 6763-6768.
22. Cong, S.Y., Pepers, B.A., Roos, R.A., van Ommen, G.J. and Dorsman, J.C. (2006) Small N-terminal mutant huntingtin fragments, but not wild type, are mainly present in monomeric form: Implications for pathogenesis. Exp. Neurol., 199, 257-264.
23. Lai, T.S., Liu, Y., Tucker, T., Daniel, K.R., Sane, D.C., Toone, E., Burke, J.R., Strittmatter, W.J. and Greenberg, C.S. (2008) Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem. Biol., 15, 969-978.
24. Chun, W., Lesort, M., Tucholski, J., Faber, P.W., MacDonald, M.E., Ross, C.A. and Johnson, G.V. (2001) Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells. Neurobiol. Dis., 8, 391-404.
25. Kim, Y.J., Yi, Y., Sapp, E., Wang, Y., Cuiffo, B., Kegel, K.B., Qin, Z.H., Aronin, N. and DiFiglia, M. (2001) Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc. Natl Acad. Sci. USA, 98 12784-12789.
26. Li, L.B., Xu, K. and Bonini, N.M. (2007) Suppression of polyglutamine toxicity by the yeast Sup35 prion domain in Drosophila. J. Biol. Chem., 282, 37694-37701.
27. Paulson, H.L., Das, S.S., Crino, P.B., Perez, M.K., Patel, S.C., Gotsdiner, D., Fischbeck, K.H. and Pittman, R.N. (1997) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol., 41, 453-462.